Heart failure & cardiomyopathies
Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma
Authors' conclusion
Pre-existing HF in older patients with newly diagnosed HL is common and associated with higher 1-year mortality.
Study context
- Population
- Patients aged ≥65 years with newly diagnosed Hodgkin lymphoma, SEER-Medicare 1999–2016
- Participants
- 3,348 patients
- Exposure
- Pre-existing heart failure (HF) vs no pre-existing HF
- Pre-existing HFn = 437
- Outcome
- Prevalence of pre-existing HF and its association with cancer treatment and cause-specific mortality
Methodological detailsSEER-Medicare linked data
- SEER-Medicare linked data
Main finding
As reported in the abstract
Pre-existing HF
13.1%
437
Pre-existing HF vs No pre-existing HFEstimate (95% CI)
Anthracycline-based chemotherapy
OR 0.42(0.29–0.60)
Lymphoma mortality
HR 1.25(1.06–1.46)
CV mortality
HR 2.57(1.96–3.36)
Observational data: associations, not effects.
Further findings
| Outcome | Pre-existing HF | No pre-existing HF |
|---|---|---|
| Lymphoma mortality cumulative incidence · 1 year | 37.4% (95% CI 35.5%–39.5%) | 26.3% (95% CI 25.0%–27.6%) |
Use of cardioprotective dexrazoxane or liposomal doxorubicin
- Used in all patients
- 4.2%
Original publication
Impact of Preexisting Heart Failure on Treatment and Outcomes in Older Patients With Hodgkin Lymphoma. JACC CardioOncol. Published 16 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →